A Phase 2, Single-Center, Randomized, Double- Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution 1% in Subjects Diagnosed With Dry Eye Disease
Latest Information Update: 26 Oct 2023
At a glance
- Drugs IC 265 (Primary)
- Indications Dry eyes
- Focus Adverse reactions; Therapeutic Use
- Sponsors IACTA Pharmaceuticals
- 20 Oct 2023 Status changed from not yet recruiting to recruiting.
- 08 Aug 2023 Status changed from planning to not yet recruiting.
- 07 Jan 2021 According to an IACTA Pharmaceuticals media release, IC 265, is ready to enter a Phase 2 clinical study with data outcomes expected in 2022